For research use only. Not for therapeutic Use.
CPDA is a novel potent SH2 domain-containing inositol phosphatase 2 (SHIP2) inhibitor.
CPDA enhances insulin signaling.
CPDA greatly improves abnormal glucose metabolism in diabetic animals. CPDA improves the abnormal glucose metabolism in db/db mice.
| Catalog Number | I001594 |
| CAS Number | 1415834-63-7 |
| Synonyms | N-[4-[(4-chlorophenyl)methoxy]pyridin-2-yl]-2-(2,6-difluorophenyl)acetamide |
| Molecular Formula | C20H15ClF2N2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H15ClF2N2O2/c21-14-6-4-13(5-7-14)12-27-15-8-9-24-19(10-15)25-20(26)11-16-17(22)2-1-3-18(16)23/h1-10H,11-12H2,(H,24,25,26) |
| InChIKey | GISJHCLTIVIGLX-UHFFFAOYSA-N |
| SMILES | C1=CC(=C(C(=C1)F)CC(=O)NC2=NC=CC(=C2)OCC3=CC=C(C=C3)Cl)F |
| Reference | [1]. Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2). Eur J Med Chem. 2013 Apr;62:649-660. |
